Chemotherapy-induced Thrombocytopenia

Hematology
4
Pipeline Programs
2
Companies
3
Clinical Trials
1
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
2
1
1
Early DiscoveryClinical DevelopmentMarket

On Market (1)

Approved therapies currently available

Amgen
NPLATEApproved
romiplostim
Amgen
Thrombopoietin Receptor Agonist [EPC]subcutaneous2008

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Amgen
AmgenTHOUSAND OAKS, CA
1 program
1
1
RomiplostimPhase 31 trial
Active Trials
NCT03362177Completed165Est. Jan 2025
Qilu Pharmaceutical
Qilu PharmaceuticalChina - Jinan
2 programs
2
QL0911Phase 2/31 trial
QL0911Phase 2/31 trial
Active Trials
NCT05851027CompletedEst. Sep 2021
NCT05554913CompletedEst. Feb 2024

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
AmgenRomiplostim
Qilu PharmaceuticalQL0911
Qilu PharmaceuticalQL0911

Clinical Trials (3)

Total enrollment: 165 patients across 3 trials

NCT03362177AmgenRomiplostim

Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Gastrointestinal, Pancreatic, or Colorectal Cancer

Start: Sep 2019Est. completion: Jan 2025165 patients
Phase 3Completed
NCT05554913Qilu PharmaceuticalQL0911

Evaluating the Efficacy and Safety of QL0911 in the Prevention of Chemotherapy- Induced Thrombocytopenia

Start: Nov 2022Est. completion: Feb 2024
Phase 2/3Completed
NCT05851027Qilu PharmaceuticalQL0911

Evaluating the Efficacy and Safety of QL0911 in Chemotherapy- Induced Thrombocytopenia

Start: Jan 2021Est. completion: Sep 2021
Phase 2/3Completed

Related Jobs in Hematology

Délégué Médical LLC/Myélome (H/F) - secteurToulouse

Johnson & Johnson
Issy-les-Moulineaux, France
Yesterday

MSL Hematología L - Sur

Johnson & Johnson
Sevilla, Spain
Yesterday

Senior Manager – Strategy & Business Transformation

Johnson & Johnson
Mumbai, India
Yesterday

Sr. Director Marketing

Genetix Biotherapeutics
Somerville, Massachusetts, United States
4d ago
From $270K/yr

Key Account Specialist Hematology

Johnson & Johnson
Beirut, Lebanon
4d ago

Hematology Field Medical Director, non-MD

Pfizer
Remote
4d ago
$177K - $294K/yr

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs — potential near-term approvals
2 companies competing in this space

Related Indications

Anemia(92)Myelofibrosis(21)Polycythemia Vera(16)Primary Immune Thrombocytopenia(15)Primary Myelofibrosis(14)Immune Thrombocytopenia(12)Thrombocytopenia(11)Beta-Thalassemia(10)Aplastic Anemia(7)Anemia of Chronic Kidney Disease(7)